MX2015009617A - Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico. - Google Patents

Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.

Info

Publication number
MX2015009617A
MX2015009617A MX2015009617A MX2015009617A MX2015009617A MX 2015009617 A MX2015009617 A MX 2015009617A MX 2015009617 A MX2015009617 A MX 2015009617A MX 2015009617 A MX2015009617 A MX 2015009617A MX 2015009617 A MX2015009617 A MX 2015009617A
Authority
MX
Mexico
Prior art keywords
crystalline forms
chlorophenoxy
cyano
carbonyl
hydroxy
Prior art date
Application number
MX2015009617A
Other languages
English (en)
Other versions
MX360048B (es
Inventor
Claudia Witschi
Michael P Arend
Jung Min Park
Michael D Thompson
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015009617(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of MX2015009617A publication Critical patent/MX2015009617A/es
Publication of MX360048B publication Critical patent/MX360048B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

La presente descripción se refiere a formas cristalinas de ácido {[1-ciano-5-(4-clorofenoxi)-4-hidrox-soquinoIin-3-carbonil]-amino }- acético (Compuesto A), el proceso para preparar formas cristalinas de Compuesto A, las composiciones farmacéuticas que las contienen y los métodos de uso de las mismas.
MX2015009617A 2013-01-24 2014-01-23 Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico. MX360048B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361756361P 2013-01-24 2013-01-24
PCT/US2014/012780 WO2014116849A1 (en) 2013-01-24 2014-01-23 Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Publications (2)

Publication Number Publication Date
MX2015009617A true MX2015009617A (es) 2016-04-20
MX360048B MX360048B (es) 2018-10-19

Family

ID=50073508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009617A MX360048B (es) 2013-01-24 2014-01-23 Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.

Country Status (16)

Country Link
US (1) US9643928B2 (es)
EP (1) EP2951159B1 (es)
JP (1) JP6437456B2 (es)
KR (1) KR102233081B1 (es)
CN (1) CN105452227B (es)
AU (1) AU2014209319B2 (es)
CA (1) CA2899024C (es)
DK (1) DK2951159T3 (es)
ES (1) ES2694297T3 (es)
HK (1) HK1217331A1 (es)
IL (1) IL240066B (es)
MX (1) MX360048B (es)
RU (1) RU2666144C2 (es)
SG (2) SG10202009266PA (es)
TW (1) TWI685487B (es)
WO (1) WO2014116849A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102977016B (zh) 2003-06-06 2015-01-14 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US8927591B2 (en) 2008-11-14 2015-01-06 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
KR20220164068A (ko) 2012-07-16 2022-12-12 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
PT2872487T (pt) 2012-07-16 2017-05-15 Fibrogen Inc Processo para a preparação de compostos isoquinolina
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
ES2694297T3 (es) 2013-01-24 2018-12-19 Fibrogen, Inc. Formas cristalinas de ácido {[1-ciano-5-(4-clorofenoxi)-4-hidroxi-isoquinolina-3-carbonilo]-amino}-acético
KR20210104173A (ko) 2013-06-06 2021-08-24 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
EP0626178A1 (de) 1993-05-17 1994-11-30 Ciba-Geigy Ag Verwendung von Hemmstoffen von HIV-Aspartatproteasen zur Bekämpfung von Tumorerkrankungen
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE59401923D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
DE69736812T2 (de) 1996-11-27 2007-08-09 Bristol-Myers Squibb Pharma Co. Neue integrin rezeptor antagonisten
WO1998050346A2 (en) 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
GB9707830D0 (en) 1997-04-18 1997-06-04 Smithkline Beecham Plc Novel compounds
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AU2002241154A1 (en) 2001-03-21 2002-10-03 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
US6716866B2 (en) 2001-06-13 2004-04-06 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
JP2005505507A (ja) 2001-06-13 2005-02-24 ジーンソフト ファーマシューティカルズ インコーポレイテッド 抗感染活性を有するイソキノリン化合物
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
CA2468083C (en) 2001-12-06 2016-02-23 Fibrogen, Inc. Use of heterocyclic carboxamides to treat anemia
GB0206711D0 (en) 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
CN102977016B (zh) 2003-06-06 2015-01-14 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CN100418948C (zh) 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
JP2008507097A (ja) 2004-07-15 2008-03-06 パワープリサイス・ソリューションズ・インコーポレーテッド ワンタイム動作状態検出方法および装置
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
ATE513833T1 (de) 2005-03-02 2011-07-15 Fibrogen Inc Thienopyridinverbindungen und verfahren zu ihrer verwendung
JP5390184B2 (ja) 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
DE602006014843D1 (de) 2005-06-15 2010-07-22 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
KR101446499B1 (ko) * 2006-01-27 2014-10-06 피브로겐, 인크. 저산소증 유발가능 인자(ｈｉｆ)를 안정시키는 시아노이소퀴놀린 화합물
CN101420980A (zh) 2006-02-16 2009-04-29 菲布罗根公司 治疗中风的化合物和方法
RU2461557C2 (ru) 2006-04-04 2012-09-20 Файброджен, Инк. Соединения пирроло- и тиазолопиридина (варианты) и фармацевтическая композиция на их основе
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
WO2009075826A1 (en) * 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for increasing white blood cells
ES2694297T3 (es) 2013-01-24 2018-12-19 Fibrogen, Inc. Formas cristalinas de ácido {[1-ciano-5-(4-clorofenoxi)-4-hidroxi-isoquinolina-3-carbonilo]-amino}-acético

Also Published As

Publication number Publication date
AU2014209319A1 (en) 2015-08-27
RU2666144C2 (ru) 2018-09-06
IL240066A0 (en) 2015-09-24
AU2014209319B2 (en) 2018-04-19
TWI685487B (zh) 2020-02-21
ES2694297T3 (es) 2018-12-19
CN105452227B (zh) 2018-05-29
KR102233081B1 (ko) 2021-03-29
CA2899024A1 (en) 2014-07-31
HK1217331A1 (zh) 2017-01-06
CN105452227A (zh) 2016-03-30
TW201444800A (zh) 2014-12-01
RU2015134420A (ru) 2017-03-03
CA2899024C (en) 2022-01-04
WO2014116849A1 (en) 2014-07-31
SG10202009266PA (en) 2020-10-29
EP2951159B1 (en) 2018-08-22
JP6437456B2 (ja) 2018-12-12
DK2951159T3 (en) 2018-11-19
EP2951159A1 (en) 2015-12-09
US9643928B2 (en) 2017-05-09
US20160002170A1 (en) 2016-01-07
MX360048B (es) 2018-10-19
SG11201505748UA (en) 2015-08-28
IL240066B (en) 2019-08-29
KR20150129679A (ko) 2015-11-20
JP2016505071A (ja) 2016-02-18

Similar Documents

Publication Publication Date Title
IN2015KN00262A (es)
MX360048B (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
MX357906B (es) COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(ß-D-GLU COPIRANOS-1-IL)-BENCENO, MÉTODOS PARA SU PREPARACIÓN Y SU USO PARA PREPARAR MEDICAMENTOS.
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
MX2013000009A (es) Procedimiento de preparacion de la sal de l-arginina de perindoprilo.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
PH12016500577B1 (en) Piperazine derivatives and the use thereof as medicament
IN2013CH04906A (es)
WO2014141294A3 (en) An improved process for the synthesis of melphalan and the hydrochloride salt
MX2016009667A (es) Forma cristalina alfa del compuesto a monobenzoato y método de preparación de la misma y composición farmacéutica que comprende la misma.
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
MX2015015746A (es) Proceso para la preparacion de arformoterol o sal del mismo.
IN2013MU04056A (es)
MX358995B (es) Forma amorfa estabilizada de agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen.
WO2012150607A3 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
IN2013CH04314A (es)
IN2013MU03508A (es)
IN2014DE01203A (es)
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
IN2013CH04330A (es)
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
WO2015001565A3 (en) "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof"
IN2013MU03610A (es)
IN2014DN10683A (es)
IN2013MU00777A (es)

Legal Events

Date Code Title Description
FG Grant or registration